Bayer receives EU approval for continuous infusion of its Kogenate treatment |
|
|
|
Published
:
Thu, 08 Feb 2007 14:30 |
FRANKFURT (AFX) - Bayer AG said it Bayer HealthCare unit has received EU approval for continuous infusion of its Kogenate treatment for hemophilia A patients undergoing major surgery.Bayer HealthCare is the first to be granted the 'continuous infusion' indication by the European Commission for all EU countries, said the company in a statement.krysia.diver@afxnews.comkd/rarCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1617.01 |
+17.95 (
1.13 %)
|
| SYMBOL (
2009-01-08 ) |
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
|
| Portfolio
Manager |
|
|
|